MCID: LNG015
MIFTS: 50

Lingual-Facial-Buccal Dyskinesia

Categories: Neuronal diseases

Aliases & Classifications for Lingual-Facial-Buccal Dyskinesia

MalaCards integrated aliases for Lingual-Facial-Buccal Dyskinesia:

Name: Lingual-Facial-Buccal Dyskinesia 12 15 71
Orofacial Dyskinesia 29 6
Oro-Facial Dyskinesia 12
Dyskinesias 43

Classifications:



External Ids:

Disease Ontology 12 DOID:9854
ICD9CM 34 333.82
MeSH 43 D020820
SNOMED-CT 67 49386006
ICD10 32 G24.4
UMLS 71 C0152115

Summaries for Lingual-Facial-Buccal Dyskinesia

MalaCards based summary : Lingual-Facial-Buccal Dyskinesia, also known as orofacial dyskinesia, is related to tardive dyskinesia and schizoaffective disorder, and has symptoms including spasmodic torticollis An important gene associated with Lingual-Facial-Buccal Dyskinesia is GNAO1 (G Protein Subunit Alpha O1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Beta-Adrenergic Signaling. The drugs Zonisamide and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include brain, subthalamic nucleus and lung, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Lingual-Facial-Buccal Dyskinesia

Diseases related to Lingual-Facial-Buccal Dyskinesia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 807)
# Related Disease Score Top Affiliating Genes
1 tardive dyskinesia 33.4 DRD3 DRD2
2 schizoaffective disorder 31.2 DRD4 DRD3 DRD2
3 neuroleptic malignant syndrome 30.9 DRD3 DRD2 DRD1
4 chorea, childhood-onset, with psychomotor retardation 30.8 GNAO1 CSTB
5 dyskinetic cerebral palsy 30.6 JRK GNAO1
6 early-onset schizophrenia 30.6 DRD2 DRD1
7 blepharospasm 30.5 PANK2 OMD JRK DRD5
8 parkinson disease, late-onset 30.4 SLC6A3 SLC18A2 DRD5 DRD4 DRD3 DRD2
9 oromandibular dystonia 30.4 VPS13A PANK2 OMD
10 cervical dystonia 30.4 OMD JRK DRD5
11 choreoacanthocytosis 30.4 XK VPS13A PANK2 KEL
12 amnestic disorder 30.3 LGI1 DRD2 DRD1
13 hemidystonia 30.3 LGI1 JRK DRD2
14 gastroparesis 30.3 DRD5 DRD4 DRD3 DRD2 DRD1
15 sleep disorder 30.2 SLC6A3 HTR2C DRD2
16 borderline personality disorder 30.2 SLC6A3 HTR2C DRD2
17 supranuclear palsy, progressive, 1 30.2 SLC6A3 DRD5 DRD2
18 alcohol use disorder 30.1 SLC6A3 HTR2C DRD3 DRD2 DRD1
19 schizophreniform disorder 30.1 DRD5 DRD4 DRD3 DRD2 DRD1
20 chorea, benign hereditary 30.1 GNAO1 CSTB
21 personality disorder 30.0 SLC6A3 HTR2C DRD4 DRD3 DRD2
22 status epilepticus 30.0 LGI1 GRIN1 DRD2
23 mental depression 30.0 SLC6A3 HTR2C DRD4 DRD3 DRD2 DRD1
24 mutism 30.0 SLC6A3 LGI1 GRIN1
25 neurodegeneration with brain iron accumulation 1 30.0 XK VPS13A PANK2
26 tic disorder 30.0 SLC6A3 SLC18A2 DRD5 DRD4 DRD3 DRD2
27 bipolar i disorder 30.0 HTR2C DRD4 DRD3 DRD2 DRD1
28 huntington disease 30.0 XK VPS13A SLC6A3 GRIN1 DRD2 DRD1
29 major depressive disorder 29.9 SLC6A3 HTR2C DRD4 DRD3 DRD2 DRD1
30 focal hand dystonia 29.9 PANK2 JRK DRD2
31 hyperprolactinemia 29.9 HTR2C DRD4 DRD2
32 anxiety 29.9 SLC6A3 HTR2C DRD4 DRD3 DRD2
33 migraine with or without aura 1 29.9 SLC6A3 HTR2C DRD5 DRD4 DRD3 DRD2
34 obsessive-compulsive disorder 29.9 SLC6A3 HTR2C DRD4 DRD3 DRD2 DRD1
35 substance abuse 29.9 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1
36 migraine without aura 29.9 DRD5 DRD4 DRD3 DRD2 DRD1
37 epilepsy 29.8 SLC6A3 LGI1 JRK GRIN1 GNAO1 CSTB
38 gilles de la tourette syndrome 29.8 SLC6A3 SLC18A2 DRD5 DRD4 DRD3 DRD2
39 impulse control disorder 29.8 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1
40 von economo's disease 29.8 SLC6A3 LGI1
41 mood disorder 29.8 SLC6A3 SLC18A2 HTR2C GRIN1 DRD4 DRD3
42 generalized anxiety disorder 29.7 SLC6A3 HTR2C DRD2
43 focal dystonia 29.7 PANK2 OMD JRK DRD5 DRD2 DRD1
44 migraine with aura 29.7 SLC6A3 HTR2C DRD2
45 drug dependence 29.6 SLC6A3 DRD3 DRD2 DRD1
46 narcolepsy 29.6 SLC6A3 SLC18A2 DRD2 DRD1
47 eating disorder 29.6 SLC6A3 HTR2C DRD3 DRD2
48 epilepsy, myoclonic juvenile 29.6 LGI1 JRK CSTB
49 restless legs syndrome 29.6 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1
50 cocaine abuse 29.5 SLC6A3 SLC18A2 DRD3 DRD2 DRD1

Graphical network of the top 20 diseases related to Lingual-Facial-Buccal Dyskinesia:



Diseases related to Lingual-Facial-Buccal Dyskinesia

Symptoms & Phenotypes for Lingual-Facial-Buccal Dyskinesia

UMLS symptoms related to Lingual-Facial-Buccal Dyskinesia:


spasmodic torticollis

GenomeRNAi Phenotypes related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-4 9.44 PANK2
2 Decreased viability GR00240-S-1 9.44 FGF14
3 Decreased viability GR00249-S 9.44 OMD
4 Decreased viability GR00301-A 9.44 PANK2
5 Decreased viability GR00381-A-1 9.44 CSTB
6 Decreased viability GR00386-A-1 9.44 CSTB DRD1 JRK VPS13A
7 Decreased viability GR00402-S-2 9.44 JRK LGI1 OMD VPS13A

MGI Mouse Phenotypes related to Lingual-Facial-Buccal Dyskinesia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 CSTB DRD1 DRD2 DRD3 DRD4 DRD5
2 growth/size/body region MP:0005378 10.15 CSTB DRD1 DRD2 DRD3 FGF14 GNAO1
3 homeostasis/metabolism MP:0005376 10.13 DRD1 DRD2 DRD3 DRD4 GNAO1 GRIN1
4 nervous system MP:0003631 10.09 CSTB DRD1 DRD2 DRD3 DRD4 DRD5
5 muscle MP:0005369 9.96 CSTB DRD1 DRD2 FGF14 HTR2C KEL
6 vision/eye MP:0005391 9.28 CSTB DRD1 DRD4 DRD5 GNAO1 GRIN1
7 taste/olfaction MP:0005394 9.26 DRD2 GRIN1 SLC18A2 SLC6A3

Drugs & Therapeutics for Lingual-Facial-Buccal Dyskinesia

Drugs for Lingual-Facial-Buccal Dyskinesia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zonisamide Approved, Investigational Phase 4 68291-97-4 5734
2
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
3
Levetiracetam Approved Phase 4 102767-28-2 441341
4
tannic acid Approved Phase 4 1401-55-4
5
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
6
Amantadine Approved Phase 4 768-94-5 2130
7
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
8
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
9
Amisulpride Approved, Investigational Phase 4 53583-79-2, 71675-85-9 2159
10
Galantamine Approved Phase 4 357-70-0 9651
11
Clozapine Approved Phase 4 5786-21-0 2818
12
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
13
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
14
Azathioprine Approved Phase 4 446-86-6 2265
15
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
16
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
17 calcium channel blockers Phase 4
18 Dopamine agonists Phase 4
19 Serotonin Receptor Agonists Phase 4
20 Serotonin 5-HT1 Receptor Agonists Phase 4
21 Hormones Phase 4
22 Anti-Infective Agents Phase 4
23 Antiviral Agents Phase 4
24 Analgesics, Non-Narcotic Phase 4
25 Analgesics Phase 4
26 Immunologic Factors Phase 4
27 Antiprotozoal Agents Phase 4
28 Antiparasitic Agents Phase 4
29 Antimalarials Phase 4
30 Gastrointestinal Agents Phase 4
31 Dopamine Antagonists Phase 4
32 Antiemetics Phase 4
33 Antidepressive Agents Phase 4
34 Hormone Antagonists Phase 4
35 Omega 3 Fatty Acid Phase 4
36 Serotonin Uptake Inhibitors Phase 4
37 Cholinesterase Inhibitors Phase 4
38 Paliperidone Palmitate Phase 4
39 Antineoplastic Agents, Hormonal Phase 4
40 glucocorticoids Phase 4
41 Anthelmintics Phase 4
42 Amebicides Phase 4
43 Chloroquine diphosphate Phase 4 50-63-5
44 Immunosuppressive Agents Phase 4
45 Anti-Inflammatory Agents Phase 4
46 Antirheumatic Agents Phase 4
47 Antimetabolites Phase 4
48 Anti-Inflammatory Agents, Non-Steroidal Phase 4
49 Antipsychotic Agents Phase 4
50 Aromatic Amino Acid Decarboxylase Inhibitors Phase 4

Interventional clinical trials:

(show top 50) (show all 256)
# Name Status NCT ID Phase Drugs
1 An Open-Label Tolerability and Exploratory Efficacy Study of Zonisamide for Dyskinesias in Parkinson's Disease Unknown status NCT03034538 Phase 4 Zonegran;Zonegran
2 Aripiprazole for Pre-Existing Neuroleptic-Induced Tardive Dyskinesia: a Prospective 26-Week Observational Study Unknown status NCT00837707 Phase 4 aripiprazole
3 A Study of the Utility of Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease Double Blind Placebo Control Crossover Pilot Study Unknown status NCT02472210 Phase 4 Botulinum Toxin
4 The Monitor of Serum Prolactin Level and Related Clinical Observations Among Individuals With Schizophrenia Spectrum Illnesses in a 3 Months Aripiprazole Trial Unknown status NCT00468533 Phase 4 Aripiprazole
5 Different Dyskinesias in Parkinson's Disease and Their Relation to Levodopa Pharmacokinetics Completed NCT00888186 Phase 4 levodopa/carbidopa
6 Efficacy and Safety of Levetiracetam Versus Placebo on Levodopa-induced Dyskinesias in Advanced Parkinson's Disease (LeLeDys Study) - A Multicenter, Randomized, Stratified, Double-blinded, Placebo-controlled Phase IV Study Completed NCT00307450 Phase 4 Levetiracetam
7 A Phase 4, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Potential for Clinical Dependence and Withdrawal Symptoms Associated With Valbenazine Completed NCT03698331 Phase 4 Valbenazine;Placebo oral capsule
8 Validation of Dyskinesia Rating Scales Completed NCT01071395 Phase 4 Amantadine;Placebo
9 D-serine Adjuvant Treatment for Parkinson's Disease Completed NCT00215904 Phase 4 D-serine (~2g/day)
10 A Randomized Controlled Trial of Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia Completed NCT00621998 Phase 4 risperidone;olanzapine
11 Tardive Dyskinesia and Cognitive Function Completed NCT00926965 Phase 4 amisulpride;Olanzapine;Conventional antipsychotics
12 Treatment of Tardive Dyskinesia With Galantamine Completed NCT00164242 Phase 4 Galantamine
13 Evaluation of the Long-term Effects of Amantadine in Parkinsonian's Suffering From Dyskinesia Induced by Levodopa: Study Randomised Double-blind, Placebo - Cessation of a Chronic Prescription. STUDY AMANDYSK. Completed NCT00632762 Phase 4 mantadix
14 The Effect of Amantadine on Movement Disorder in Ataxia-Telangiectasia Completed NCT00950196 Phase 4 amantadine sulphate
15 Augmentation of Clozapine With Paliperidone in the Treatment of Resistant Schizophrenia Randomized Controlled Study Completed NCT01279213 Phase 4 paliperidone clozapine
16 Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial Completed NCT02463331 Phase 4 Chloroquine diphosphate;prednisone;azathioprine
17 DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS Completed NCT01980745 Phase 4 Chloroquine diphosphate 250mg;Placebo
18 A Double-Blind, Randomised, Parallel-Group Comparison of Ethyl-Eicosapentaenoic Acid (Ethyl-EPA) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia Completed NCT00114595 Phase 4 eicosapentaenoic acid
19 A Phase 4, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Evaluate the Persistence of Effect and Safety of Valbenazine for the Treatment of Tardive Dyskinesia Recruiting NCT03891862 Phase 4 Valbenazine;Placebo oral capsule
20 Treatment in Advanced Parkinson's Disease: Continuous Intrajejunal Levodopa INfusion VErsus Deep Brain STimulation Recruiting NCT02480803 Phase 4 Continuous intrajejunal infusion of levodopa-carbidopa
21 Effect of Varenicline on Smoking Cessation in Patients With Schizophrenia: Evaluation of Antipsychotic Drug-Induced Neurological Symptoms as Correlates of Response Recruiting NCT03495024 Phase 4 Varenicline
22 The Effect of Deep Brain Stimulation of the Subthalamic Nucleus (STN-DBS) on Quality of Life in Comparison to Best Medical Treatment in Patients With Complicated Parkinson's Disease and Preserved Psychosocial Competence (EARLYSTIM-study) Active, not recruiting NCT00354133 Phase 4 Best Medical Treatment
23 Botulinum Toxin Type A (Botox) in the Management of Levodopa-Induced Peak-Dose Dyskinesias in Parkinson's Disease: A Double-Blind, Randomized, Placebo Controlled, Cross-Over Design Study Terminated NCT00477802 Phase 4
24 Buspirone Treatment of Iatrogenic Dyskinesias in Advanced Parkinson' Disease. Multicenter, International, Placebo-controlled, Randomised, Double Blind Trial Unknown status NCT02617017 Phase 3 Buspirone;Placebo
25 Open Label Prospective Study of High Dose Ropinirole for Motor Fluctuations and Dyskinesias in Advanced Parkinson's Disease Unknown status NCT00260793 Phase 3 Ropinirole Hydrochloride
26 Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID) Unknown status NCT02202551 Phase 3 ADS-5102
27 Levetiracetam Treatment of Tardive Dyskinesia Completed NCT00291213 Phase 3 levetiracetam;placebo
28 A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Completed NCT02195700 Phase 2, Phase 3 SD-809;Placebo
29 A Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia Completed NCT02291861 Phase 3 SD-809;Placebo
30 A Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02405091 Phase 3 NBI-98854
31 A Two Year Phase IIIb Randomised, Multicenter, Double-blind, SINEMET Controlled, Parallel Group, Flexible Dose Study, to Assess the Effectiveness of Controlled Release Ropinirole add-on Therapy to L-dopa at Increasing the Time to Onset of Dyskinesia in Parkinson's Disease Subjects. Completed NCT00363727 Phase 3 ropinirole controlled-release (REQUIP CR) for RLS
32 A Double-Blind, Placebo-Controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan in Patients With Parkinson's Disease Suffering From Treatment-Associated Dyskinesia Completed NCT00105521 Phase 3 Sarizotan;Placebo
33 A Double-blind, Placebo-controlled, Multicenter, Multinational Phase III Study to Evaluate the Safety and Efficacy of Sarizotan HCl 1 mg b.i.d. in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia Completed NCT00105508 Phase 3 Sarizotan;Placebo
34 Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects Completed NCT00360568 Phase 3 Levodopa-carbidopa intestinal gel
35 Open-Label Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia Completed NCT02736955 Phase 3 Valbenazine
36 A Double-Blind, Randomised, Parallel-Group Comparison of Extract of Ginkgo Biloba(EGB-761) Versus Placebo as Add-on Medication in Patients With Established Tardive Dyskinesia Completed NCT00672373 Phase 3 Extract of Ginkgo Biloba (EGb-761 capsules);Placebo
37 An Open-label, Randomized 12 Week Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease DYSCOVER (DYSkinesia COmparative Interventional Trial on Duodopa VERsus Oral Medication) Completed NCT02799381 Phase 3 ABT-SLV187;optimized antiparkinsonian treatment
38 Double-blind, Placebo-controlled, Randomized, Multicentre Phase II/III Study to Evaluate the Efficacy and Safety of Lisuride, Applied Subcutaneously by Means of a Minipump in Patients With Advanced Parkinson's Disease Refractory to Conventional Oral Therapy Completed NCT00408915 Phase 3 Continuous Subcutaneous Lisuride Infusion
39 Multicenter, Placebo Controlled, Randomized, Double-Blinded Study: Coenzyme Q10 Nanodispersion Versus Placebo as Symptomatic Treatment in Parkinson's Disease Completed NCT00180037 Phase 3 Coenzyme Q10 Nanodispersion (Nanoquinone);Placebo
40 A 16-week, Double-Blind, Placebo-Controlled, Randomised, Parallel-Group, Multicentre, International Study to Evaluate the Efficacy and Safety of 40 mg/Day KW-6002 (Istradefylline) and That of Entacapone Versus Placebo as Treatment for Parkinson's Disease in Patients With Motor Response Complications on Levodopa Therapy. Completed NCT00199394 Phase 3 Istradefylline (KW-6002)
41 Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia (EASED Study) Completed NCT01397422 Phase 2, Phase 3 ADS-5102 (extended release amantadine HCl)
42 Efficacy and Safety of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease Patients (EASE LID Study) Completed NCT02136914 Phase 3 ADS-5102
43 ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson's Disease Patients With Levodopa-Induced Dyskinesia (EASE LID 3 Study) Completed NCT02274766 Phase 3 ADS-5102
44 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel, Fixed-Dose Study to Assess the Efficacy, Safety, and Tolerability of NBI-98854 for the Treatment of Tardive Dyskinesia Completed NCT02274558 Phase 3 NBI-98854;Placebo
45 Deep Brain Stimulation for Parkinson's Disease Trial Completed NCT00053625 Phase 3
46 A 6-Month, Open-Label, Single-Arm Safety Study of Flexibly Dosed Paliperidone Extended Release (1.5 - 12 mg/Day) in the Treatment of Adolescents (12 to 17 Years of Age) With Schizophrenia Completed NCT00488319 Phase 3 Paliperidone ER
47 Study of Efficacy and Acceptability of Tetrabenazine in the Late Dyskinetic Syndrome With Neuroleptics: A Randomized, Parallel Group, Double-blind Placebo Controlled Multicentre Trial Completed NCT01543321 Phase 3 Tetrabenazine;Placebo
48 Therapeutic Use of Piracetam for Treatment of Patients Suffering From Tardive Dyskinesia: a Double Blind, Placebo-Controlled Crossover Study Completed NCT00190008 Phase 3 piracetam
49 Effect of Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Recruiting NCT03790345 Phase 2, Phase 3 Pyridoxine;Cobalamin;Placebo Oral Tablet
50 Long Term Aerobic Exercise to Slow Progression in Parkinson's Disease Recruiting NCT03808675 Phase 2, Phase 3

Search NIH Clinical Center for Lingual-Facial-Buccal Dyskinesia

Cochrane evidence based reviews: dyskinesias

Genetic Tests for Lingual-Facial-Buccal Dyskinesia

Genetic tests related to Lingual-Facial-Buccal Dyskinesia:

# Genetic test Affiliating Genes
1 Orofacial Dyskinesia 29

Anatomical Context for Lingual-Facial-Buccal Dyskinesia

MalaCards organs/tissues related to Lingual-Facial-Buccal Dyskinesia:

40
Brain, Subthalamic Nucleus, Lung, Testes, Liver, Cerebellum, Heart

Publications for Lingual-Facial-Buccal Dyskinesia

Articles related to Lingual-Facial-Buccal Dyskinesia:

(show top 50) (show all 266)
# Title Authors PMID Year
1
Combined Dendritic and Axonal Deterioration Are Responsible for Motoneuronopathy in Patient-Derived Neuronal Cell Models of Chorea-Acanthocytosis. 61
32151030 2020
2
[Acute neuropsychiatry: a confused patient and a puzzled doctor]. 61
32073794 2019
3
Influence of magnesium supplementation and L-type calcium channel blocker on haloperidol-induced movement disturbances. 61
31374223 2019
4
Correction to: Novel mutations in KMT2B offer pathophysiological insights on childhood-onset progressive dystonia. 61
31388109 2019
5
Orofacial Dyskinesia in a Young Man. 61
31545336 2019
6
Novel mutations in KMT2B offer pathophysiological insights into childhood-onset progressive dystonia. 61
31165786 2019
7
18F-FDG PET/CT: an unexpected case of Huntington's disease. 61
31043171 2019
8
Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. 61
30642806 2019
9
Anti-N-methyl-d-aspartate receptor encephalitis during pregnancy: A case report. 61
30788880 2019
10
Clinical Profile and Neuropsychiatric Outcome in Children with Anti-NMDAR Encephalitis. 61
30955001 2019
11
Severe tooth loss secondary to orofacial dyskinesias in anti-NMDA receptor encephalitis. 61
30846455 2019
12
A review for the pharmacological effect of lycopene in central nervous system disorders. 61
30616078 2019
13
Possible nitric oxide mechanism involved in the protective effect of L-theanine on haloperidol-induced orofacial dyskinesia. 61
30942195 2019
14
Infectious Trigger for Autoimmune Encephalitis: A Case Report and Literature Review. 61
31781432 2019
15
TLE1, a key player in neurogenesis, a new candidate gene for autosomal recessive postnatal microcephaly. 61
29758293 2018
16
Protective effect of hesperetin against haloperidol-induced orofacial dyskinesia and catalepsy in rats. 61
28641484 2018
17
Cannabidiol prevents haloperidol-induced vacuos chewing movements and inflammatory changes in mice via PPARγ receptors. 61
30217539 2018
18
Effect of Biperiden Treatment in Acute Orofacial and Extremity Dyskinesia With Methylphenidate Therapy. 61
28328695 2018
19
L-Theanine Decreases Orofacial Dyskinesia Induced by Reserpine in Rats. 61
29629512 2018
20
Anti-NMDA receptor encephalitis: still unknown and underdiagnosed by physicians and especially by psychiatrists? 61
29050531 2018
21
Dexmethylphenidate Extended Release-Associated Orofacial Dyskinesia in an Adolescent with Autism Spectrum Disorder After Prolonged Use. 61
29781724 2018
22
Acute-onset Orofacial Dyskinesia with a Single Low Dose of Oral Flupentixol: A Case Report. 61
29962578 2018
23
Pediatric NMDAR encephalitis: A single center observation study with a closer look at movement disorders. 61
29396169 2018
24
Protective Effect of L-Theanine on Haloperidol-Induced Orofacial. 61
29374957 2018
25
A review of the outcome of dental implant provision in individuals with movement disorders. 61
30109299 2018
26
Management of Refractory Orofacial Dyskinesia Caused by Anti-N-methyl-d-aspartate Receptor Encephalitis Using Botulinum Toxin. 61
29520252 2018
27
Efficacy and safety of AAV2 gene therapy in children with aromatic L-amino acid decarboxylase deficiency: an open-label, phase 1/2 trial. 61
30169182 2017
28
Resveratrol Protects Against Vacuous Chewing Movements Induced by Chronic Treatment with Fluphenazine. 61
28744755 2017
29
An unusual case of refractory status epilepticus in a young lady: anti-NMDA receptor encephalitis. 61
28974594 2017
30
Serial EEG Monitoring in a Patient With Anti-NMDA Receptor Encephalitis. 61
27821481 2017
31
Behavioral and neurochemical effects of alpha lipoic acid associated with omega-3 in tardive dyskinesia induced by chronic haloperidol in rats. 61
28329449 2017
32
[Early Diagnosis of Chorea-Acanthocytosis: Orofacial Dyskinesia, Epileptic Seizures, and HyperCKemia]. 61
28561176 2017
33
Influence of magnesium supplementation on movement side effects related to typical antipsychotic treatment in rats. 61
27816557 2017
34
Clozapine-Induced Microseizures, Orofacial Dyskinesia, and Speech Dysfluency in an Adolescent with Treatment Resistant Early Onset Schizophrenia on Concurrent Lithium Therapy. 61
28835863 2017
35
Brain Calcification and Movement Disorders. 61
28097511 2017
36
Methylmalonic Acidemia with Novel MUT Gene Mutations. 61
29158924 2017
37
Ginkgo biloba leaf extract and alpha-tocopherol attenuate haloperidol-induced orofacial dyskinesia in rats: Possible implication of antiapoptotic mechanisms by preventing Bcl-2 decrease and Bax elevation. 61
27823630 2016
38
NMDA-receptor associated encephalitis in a woman with mature cystic ovarian teratoma. 61
29733562 2016
39
Crocin prevents haloperidol-induced orofacial dyskinesia: possible an antioxidant mechanism. 61
27872703 2016
40
Anti-collapsin response mediator protein 5 encephalitis masquerading as a low-grade brain tumour. 61
27247429 2016
41
Agmatine attenuates reserpine-induced oral dyskinesia in mice: Role of oxidative stress, nitric oxide and glutamate NMDA receptors. 61
27306571 2016
42
Plasmodium falciparum and Mycoplasma pneumoniae co-infection presenting with cerebral malaria manifesting orofacial dyskinesia and haemophagocytic lymphohistiocytosis. 61
27609213 2016
43
Clinical variability of neuroacanthocytosis syndromes-a series of six patients with long follow-up. 61
27310290 2016
44
Harpagophytum Procumbens Ethyl Acetate Fraction Reduces Fluphenazine-Induced Vacuous Chewing Movements and Oxidative Stress in Rat Brain. 61
26732278 2016
45
Non-Wilsonian hepatolenticular degeneration: Clinical and MRI observations in four families from south India. 61
26765764 2016
46
Diminution of falsely elevated tumour markers following immunosuppression for systemic lupus erythematosus with neurological involvement. 61
27048397 2016
47
Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation. 61
26712377 2016
48
Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat. 61
24464858 2015
49
Orofacial Dyskinesia in Elderly. 61
30838247 2015
50
Determining Whether a Definitive Causal Relationship Exists Between Aripiprazole and Tardive Dyskinesia and/or Dystonia in Patients With Major Depressive Disorder: Part 1. 61
26348804 2015

Variations for Lingual-Facial-Buccal Dyskinesia

ClinVar genetic disease variations for Lingual-Facial-Buccal Dyskinesia:

6 ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 WDR73 NM_032856.5(WDR73):c.42-1G>CSNV Pathogenic 812997 15:85196931-85196931 15:84653700-84653700
2 CSTB NM_000100.3(CSTB):c.202C>T (p.Arg68Ter)SNV Pathogenic 8396 rs74315442 21:45194178-45194178 21:43774297-43774297
3 CSTB NM_000100.3(CSTB):c.67-1G>CSNV Pathogenic/Likely pathogenic 8395 rs147484110 21:45194641-45194641 21:43774760-43774760
4 GNAO1 NM_020988.3(GNAO1):c.709G>A (p.Glu237Lys)SNV Pathogenic/Likely pathogenic 420523 rs1064794533 16:56370758-56370758 16:56336846-56336846
5 GNAO1 NM_020988.3(GNAO1):c.545C>T (p.Thr182Ile)SNV Likely pathogenic 812779 16:56368721-56368721 16:56334809-56334809
6 HERC2 NM_004667.5(HERC2):c.5045A>G (p.Asn1682Ser)SNV Uncertain significance 599009 rs140073033 15:28474681-28474681 15:28229535-28229535
7 RYR1 NM_000540.2(RYR1):c.1312G>C (p.Glu438Gln)SNV Uncertain significance 599010 rs765668209 19:38943526-38943526 19:38452886-38452886
8 46;XX;t(2;14)(q21;q24.3)dnTranslocation Uncertain significance 267947

Expression for Lingual-Facial-Buccal Dyskinesia

Search GEO for disease gene expression data for Lingual-Facial-Buccal Dyskinesia.

Pathways for Lingual-Facial-Buccal Dyskinesia

Pathways related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.39 XK KEL HTR2C GRIN1 DRD5 DRD4
2
Show member pathways
12.61 GNAO1 DRD5 DRD4 DRD3 DRD2 DRD1
3
Show member pathways
12.28 SLC6A3 SLC18A2 GRIN1 GNAO1 DRD5 DRD4
4 12.15 GRIN1 DRD5 DRD2 DRD1
6 12.09 GRIN1 DRD5 DRD4 DRD3 DRD2 DRD1
7
Show member pathways
12.08 HTR2C GRIN1 DRD5 DRD1
8
Show member pathways
11.79 SLC6A3 SLC18A2 GRIN1 DRD2 DRD1
9 11.77 SLC18A2 HTR2C GNAO1
10
Show member pathways
11.74 GRIN1 DRD4 DRD2 DRD1
11
Show member pathways
11.67 SLC18A2 DRD4 DRD3 DRD2
12
Show member pathways
11.67 HTR2C DRD5 DRD4 DRD3 DRD2 DRD1
13 11.64 HTR2C DRD2 DRD1
14 10.85 HTR2C DRD2
15
Show member pathways
10.53 SLC6A3 SLC18A2 DRD5 DRD4 DRD3 DRD2

GO Terms for Lingual-Facial-Buccal Dyskinesia

Cellular components related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.33 XK SLC6A3 SLC18A2 KEL HTR2C GRIN1
2 synapse GO:0045202 9.91 LGI1 HTR2C GRIN1 DRD5 DRD3 DRD2
3 integral component of plasma membrane GO:0005887 9.91 SLC6A3 SLC18A2 HTR2C GRIN1 DRD5 DRD4
4 dendrite GO:0030425 9.8 HTR2C GRIN1 GNAO1 DRD4 DRD2 DRD1
5 synaptic vesicle membrane GO:0030672 9.69 SLC18A2 DRD3 DRD2
6 GABA-ergic synapse GO:0098982 9.67 DRD3 DRD2 DRD1
7 integral component of presynaptic membrane GO:0099056 9.65 SLC6A3 DRD2 DRD1
8 cell GO:0005623 9.65 XK VPS13A KEL HTR2C GRIN1 DRD5
9 ciliary membrane GO:0060170 9.63 DRD5 DRD2 DRD1
10 glutamatergic synapse GO:0098978 9.63 LGI1 GRIN1 DRD4 DRD3 DRD2 DRD1
11 integral component of postsynaptic membrane GO:0099055 9.61 SLC6A3 DRD2 DRD1
12 non-motile cilium GO:0097730 9.58 DRD5 DRD2 DRD1
13 synaptic cleft GO:0043083 9.54 LGI1 GRIN1
14 9+0 non-motile cilium GO:0097731 9.52 DRD5 DRD1
15 dopaminergic synapse GO:0098691 8.92 SLC6A3 SLC18A2 DRD3 DRD2

Biological processes related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

(show top 50) (show all 68)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.34 HTR2C GNAO1 FGF14 DRD5 DRD4 DRD3
2 G protein-coupled receptor signaling pathway GO:0007186 10.25 HTR2C GNAO1 DRD5 DRD4 DRD3 DRD2
3 response to drug GO:0042493 10.07 SLC6A3 HTR2C DRD3 DRD2 DRD1
4 chemical synaptic transmission GO:0007268 10.04 SLC18A2 HTR2C GRIN1 DRD5 DRD4
5 cell-cell signaling GO:0007267 10.03 FGF14 DRD5 DRD3 DRD2 DRD1
6 response to ethanol GO:0045471 9.95 SLC6A3 GRIN1 DRD3 DRD2
7 adenylate cyclase-modulating G protein-coupled receptor signaling pathway GO:0007188 9.92 GNAO1 DRD5 DRD3 DRD2 DRD1
8 response to toxic substance GO:0009636 9.9 SLC18A2 DRD3 DRD2
9 social behavior GO:0035176 9.9 VPS13A GRIN1 DRD4 DRD3
10 learning GO:0007612 9.89 GRIN1 DRD3 DRD1
11 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.88 HTR2C DRD4 DRD1
12 visual learning GO:0008542 9.88 GRIN1 DRD3 DRD2 DRD1
13 adult locomotory behavior GO:0008344 9.87 GRIN1 DRD4 CSTB
14 positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway GO:0051482 9.87 HTR2C DRD3 DRD2 DRD1
15 cellular calcium ion homeostasis GO:0006874 9.87 XK KEL HTR2C GRIN1 DRD5 DRD4
16 feeding behavior GO:0007631 9.85 HTR2C DRD2 DRD1
17 associative learning GO:0008306 9.85 GRIN1 DRD5 DRD2 DRD1
18 behavioral fear response GO:0001662 9.83 HTR2C DRD4 DRD1
19 response to morphine GO:0043278 9.83 GRIN1 DRD3 DRD2
20 negative regulation of blood pressure GO:0045776 9.82 DRD5 DRD3 DRD2
21 adenylate cyclase-activating adrenergic receptor signaling pathway GO:0071880 9.81 DRD5 DRD3 DRD2 DRD1
22 negative regulation of protein secretion GO:0050709 9.8 DRD4 DRD3 DRD2
23 arachidonic acid secretion GO:0050482 9.8 DRD4 DRD3 DRD2
24 response to cocaine GO:0042220 9.8 SLC6A3 DRD5 DRD3 DRD2 DRD1
25 negative regulation of voltage-gated calcium channel activity GO:1901386 9.79 DRD4 DRD3 DRD2
26 behavioral response to ethanol GO:0048149 9.79 DRD4 DRD3 DRD2
27 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.78 DRD5 DRD3 DRD1
28 behavioral response to cocaine GO:0048148 9.78 DRD4 DRD3 DRD2 DRD1
29 regulation of dopamine metabolic process GO:0042053 9.77 SLC6A3 DRD4 DRD1
30 synaptic transmission, dopaminergic GO:0001963 9.77 DRD5 DRD4 DRD3 DRD2 DRD1
31 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.76 DRD4 DRD3 DRD2
32 dopamine metabolic process GO:0042417 9.76 DRD4 DRD3 DRD2 DRD1
33 transmission of nerve impulse GO:0019226 9.74 DRD5 DRD1
34 response to iron ion GO:0010039 9.74 SLC6A3 DRD2
35 negative regulation of cytosolic calcium ion concentration GO:0051481 9.74 DRD3 DRD2
36 startle response GO:0001964 9.74 GRIN1 DRD2
37 long-term synaptic depression GO:0060292 9.73 DRD5 DRD1
38 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.73 DRD3 DRD2
39 positive regulation of renal sodium excretion GO:0035815 9.73 DRD3 DRD2
40 grooming behavior GO:0007625 9.73 DRD2 DRD1
41 dopamine transport GO:0015872 9.73 SLC6A3 SLC18A2 DRD1
42 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.73 DRD5 DRD3 DRD2 DRD1
43 G protein-coupled receptor internalization GO:0002031 9.72 DRD3 DRD2
44 striatum development GO:0021756 9.72 DRD2 DRD1
45 regulation of postsynaptic neurotransmitter receptor internalization GO:0099149 9.72 DRD4 DRD3
46 regulation of potassium ion transport GO:0043266 9.72 DRD3 DRD2
47 peristalsis GO:0030432 9.72 DRD2 DRD1
48 adenohypophysis development GO:0021984 9.71 SLC6A3 DRD2
49 monoamine transport GO:0015844 9.71 SLC6A3 SLC18A2
50 hyaloid vascular plexus regression GO:1990384 9.71 SLC6A3 DRD2

Molecular functions related to Lingual-Facial-Buccal Dyskinesia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor activity GO:0004930 9.91 HTR2C DRD5 DRD4 DRD3 DRD2 DRD1
2 drug binding GO:0008144 9.65 SLC6A3 HTR2C DRD4 DRD3 DRD2
3 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.5 DRD4 DRD3 DRD2
4 adrenergic receptor activity GO:0004935 9.46 DRD5 DRD3 DRD2 DRD1
5 monoamine transmembrane transporter activity GO:0008504 9.4 SLC6A3 SLC18A2
6 dopamine neurotransmitter receptor activity, coupled via Gs GO:0001588 9.37 DRD5 DRD1
7 dopamine neurotransmitter receptor activity GO:0004952 9.35 DRD5 DRD4 DRD3 DRD2 DRD1
8 dopamine binding GO:0035240 9.1 SLC6A3 DRD5 DRD4 DRD3 DRD2 DRD1

Sources for Lingual-Facial-Buccal Dyskinesia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....